Angiotensin-Converting Enzyme Inhibitors Downregulate Tissue Factor Synthesis in Monocytes

Emanuela Napoleone, Angelomaria Di Santo, Marina Camera, Elena Tremoli, Roberto Lorenzet

Abstract—Angiotensin-converting enzyme (ACE) inhibitors reduce the risk of recurrent myocardial infarction in patients with left ventricular dysfunction. Tissue factor (TF), the initiator of blood coagulation, plays a pivotal role in arterial thrombosis that occurs after atherosclerotic plaque fissuring. Because monocytes synthesize TF and contain several components of the renin-angiotensin system, we investigated the possibility that ACE inhibitors could modulate monocyte TF expression. Mononuclear leukocytes from healthy volunteers were incubated with endotoxin in the presence or absence of different ACE inhibitors. Captopril reduced TF expression in endotoxin-stimulated mononuclear leukocytes, as measured by a 1-stage clotting assay and ELISA analysis, by ≈60%. The effect was dose-dependent and was attributable to ACE inhibition, given that other ACE inhibitors, such as idrapril or fosinopril, and losartan, an antagonist of the angiotensin II AT1 receptor, caused a comparable reduction in TF activity. Reverse transcriptase–polymerase chain reaction indicated that endotoxin-mediated increased levels of TF mRNA were inhibited by ACE inhibitors. Moreover, endotoxin-induced nuclear factor-κB translocation to the promoter region of the gene encoding for TF was markedly inhibited by captopril. The finding that ACE inhibitors and angiotensin II AT1 antagonists can potentially modulate TF expression by mononuclear cells has important biological and therapeutic implications for the evolution of thrombi. Our results suggest that the anti-ischemic effect of these drugs might be explained, at least in part, by their ability to reduce TF expression in monocytes. (Circ Res. 2000;86:139-143.)

Key Words: angiotensin ■ coagulation ■ leukocyte

Angiotensin-converting enzyme (ACE), a component of the renin-angiotensin system, is considered to play a central role in the maintenance of blood pressure and the regulation of fluid and electrolyte homeostasis.1 Recently, ACE inhibitors have been proposed to exert anti-ischemic effects, reducing the risk of recurrent myocardial infarction in patients with left ventricular dysfunction. In particular, ACE inhibitors cause regression of left ventricular hypertrophy and reduce mortality in patients with congestive heart failure.2–4

Although most of the effects of ACE inhibitors are generally linked to their anti-hypertensive action, numerous reports suggest alternative mechanisms related to the atherothrombotic process. The renin-angiotensin system has been implicated in the proliferative response of the vascular wall after arterial injury,5 in the synthesis of proto-oncogenes that are linked to the adaptive process of cardiovascular hypertrophy,6 in the biosynthesis of plasminogen activator inhibitor type 1 and tissue plasminogen activator,7 and in the synthesis of tumor necrosis factor and interleukin-1 by mononuclear cells.8 Recently, accumulation of ACE in areas of clustered atherosclerotic plaques and microvessel endothelial cells in human atherosclerotic plaques has been reported,9 and ACE inhibitors have been shown to reduce the extent of vascular lesions.10

Tissue factor (TF) is a transmembrane glycoprotein that, on binding to coagulation factor VII and its active form VIIa, forms the cell surface complex responsible for the coagulation sequelae, which lead to fibrin formation.11 TF is constitutively present on the surface of nonvascular cells, providing the body with a defense mechanism apt to stop the loss of blood in case of tissue injury. Although normally not present on cells in contact with blood, monocytes and endothelial cells can be induced by several agonists to synthesize and express TF on their membranes.12–14

TF gene expression is regulated principally at the level of transcription.15 In endotoxin (bacterial lipopolysaccharide)–stimulated monocytes, activation of the TF gene induces the translocation to the nucleus of c-Rel/p65 heterodimers, which belong to the family of transacting factors nuclear factor (NF)–κB, where they bind to a putative κB site in the TF promoter.16

The expression of TF on monocyte membrane is potentially involved in thrombus formation in a variety of pathological conditions such as immune-inflammatory diseases,17 septic shock,18 and cancer.19,20 Recently, monocyte TF has been proposed as the main protein responsible for the thrombotic complications of atherosclerosis. The presence of

Received July 1, 1999; accepted October 26, 1999.

From the “Antonio Taticchi” Unit for Atherosclerosis and Thrombosis (E.N., A.D.S., R.L.), Department of Vascular Medicine and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, and the Laboratory of Pharmacology of Atherosclerosis and Thrombosis (M.C., E.T.), Institute of Pharmacological Sciences, University of Milan, Italy.

Correspondence to Dr Roberto Lorenzet, Consorzio Mario Negri Sud, Via Nazionale 66030 S Maria Imbaro, Italy. E-mail lorenzet@cmns.mnegri.it

© 2000 American Heart Association, Inc.

Circulation Research is available at http://www.circresaha.org
mRNA coding for TF has been reported in macrophage foam cells and monocytes adjacent to the cholesterol clefts in atherosclerotic plaques from patients undergoing carotid endarterectomy. Moreover, macrophages isolated from carotid atherosclerotic plaques were found to express a marked procoagulant activity. In addition, a role for monocyte TF has been proposed in unstable coronary syndromes. In particular, increased expression of TF was found in athectomy specimens from patients with unstable angina or myocardial infarction.

To gain knowledge of the potential mechanism of the antithrombotic properties of ACE inhibitors, we studied their effect in the synthesis and expression of TF by human monocytes. We now offer the first direct evidence that ACE inhibitors downregulate TF expression in endotoxin-stimulated human monocytes and that this effect is mimicked by the angiotensin II AT1 receptor antagonist losartan.

**Materials and Methods**

**Cell Isolation and Culture**
Mononuclear cells were obtained from blood from healthy volunteers as previously described and were resuspended at a final concentration of 3×10⁶ cells/mL. The monocytes in this population were 25% to 30%, as assessed by nonspecific esterase staining. Monocytes were purified by using a discontinuous Percoll density gradient. The Percoll-isolated fraction contained ∼85% monocytes.

Monocytes and monocytes were incubated with endotoxin (Escherichia coli 055:B5W, Difco), captopril, irapril (Guidotti Limited), fosinopril (Bristol-Myers Squibb), or losartan (Merck & Co) in sterile, pyrogen-free stoppered test tubes at 37°C. At the end of incubation, the cells were disrupted by 3 freeze-thaw cycles and stored at −20°C until assayed.

In some experiments, freshly drawn, citrated whole blood was incubated with captopril at 37°C for 30 minutes, after which endotoxin was added, and then samples were incubated at 37°C for an additional 2 hours. Mononuclear cells were then isolated, lysed by freezing and thawing, and tested for procoagulant activity.

**Determination of TF Activity and Antigen**
Procoagulant activity was assessed by a 1-stage clotting assay. Results are expressed in arbitrary units (AU) by comparison with a standard curve obtained using a human brain thromboplastin standard (courtesy of Dr L. Poller, University of Manchester, Manchester, UK). This preparation was assigned a value of 1000 AU for a 100% value was assigned to the activity expressed by mononuclear cells incubated with endotoxin. Data are mean±SEM of 4 experiments. *P<0.05, **P<0.001.

**ACE Determination**
ACE activity was determined by the ability of the cell lysate to hydrolyze the artificial substrate H-H-L, as previously described. Mononuclear cells were cultured with or without endotoxin for 4 hours at 37°C, washed 3 times with HEPES-buffered saline containing 1.5 mmol/L CaCl₂ and 0.5 mmol/L MgCl₂, resuspended at a concentration of 5×10⁶/mL, and frozen until assayed. Known concentrations of histidyl-L-leucine were used to generate a standard curve.

**Statistical Analysis**
The results are given as mean±SEM. Statistical analysis was performed using the 1-way ANOVA.

**Results**

**Effect of ACE Inhibitors on Mononuclear Cell TF Activity**
Procoagulant activity was not detectable in freshly isolated mononuclear cells but was induced by exposure to 0.1 μg/mL endotoxin for 4 hours at 37°C (0.04±0.02 and 7.66±3.32 AU/3×10⁶ mononuclear cells; n=4, respectively). The procoagulant activity was characterized using either congenital factor–deficient plasmas or the monoclonal anti-TF antibody HTF1 (courtesy of Dr Yale Nemerson, Mt Sinai School of Medicine, New York, NY). The dependence on the presence of factor VII, factor X, and prothrombin and the inhibition of the activity observed with the anti-TF antibody indicates this activity to be attributable to TF (not shown).

When captopril was present during the incubation, TF activity was reduced in a concentration-dependent way, reaching ∼60% inhibition at a concentration of 40 μg/mL (Figure 1). The inhibition of TF activity by captopril was paralleled by a significant decrease in detectable TF antigen by ELISA analysis. Mononuclear cells expressed little TF protein on their membrane, which was dramatically increased by endotoxin (3.8±3.8 versus 859.1±245.6 pg/mL, respectively, n=3). In the presence of 20 μg/mL of captopril, TF antigen level of endotoxin-stimulated mononuclear cells was reduced to 475.6±30.3 pg/mL (P<0.05).

**Figure 1. Effect of captopril on mononuclear cell TF activity.** Mononuclear cells (3×10⁶/mL) were incubated with endotoxin (0.1 μg/mL) and with the depicted concentrations of captopril for 4 hours at 37°C. Cells were then disrupted by freezing and thawing, and TF activity was measured by a 1-stage clotting time. Results are expressed in percentage of TF activity. A 100% value was assigned to the activity expressed by mononuclear cells incubated with endotoxin. Data are mean±SEM of 4 experiments. *P<0.05, **P<0.001.
Because the captopril molecule contains a sulfhydryl group, which may confer properties other than ACE inhibition, such as free radical scavenging, we tested the activity of fosinopril and idrapril, 2 among the group of non–sulfhydryl-containing ACE inhibitors. Fosinopril and idrapril, incubated with mononuclear cells in the presence of endotoxin, reduced TF activity to a similar extent as captopril (Figure 2). This observation suggests that the reduction of TF observed in the presence of ACE inhibitors is attributable to inhibition of ACE.

We tested whether captopril was effective also when mononuclear cell TF was elicited in whole blood, which represents a condition closer to the in vivo situation. To this end, citrated whole blood was preincubated with captopril (10 μg/mL) for 30 minutes and then stimulated with endotoxin (0.01 μg/mL) for an additional period of 2 hours, after which mononuclear cells were isolated and disrupted. Endotoxin-induced TF activity in mononuclear cells (5.84±0.87 versus 0.003±0.001 AU/3×10^6 cells, with and without endotoxin, respectively, n=3), which was significantly inhibited when 10 μg/mL captopril was present during the incubation (2.5±1.01, AU/3×10^6 cells, P<0.05).

**Effect of Losartan on Mononuclear Cell TF**

Because ACE converts angiotensin I into angiotensin II and the latter binds specific receptors, namely AT_1 and AT_2, on cell membranes, and because activated monocytes have been shown to express AT_1 receptors, we tested whether blocking the receptors could affect TF generation from endotoxin-stimulated mononuclear cells. Indeed, losartan, a specific antagonist of the AT_1 receptor family, downregulated endotoxin-stimulated mononuclear cell TF activity to an extent similar to that observed with captopril (Figure 3).

**Regulation of TF mRNA Levels in Endotoxin-Stimulated Mononuclear Cells by Captopril**

To determine the steady-state levels of TF mRNA, we performed reverse transcriptase–PCR. RNA prepared from untreated control cells or from cells treated with endotoxin with or without captopril was reverse transcribed and used for parallel assay of TF and GAPDH mRNA by PCR amplification. The expected 337-bp PCR product for TF was obtained. Southern blot analysis of the PCR products was performed to evaluate TF mRNA levels. No PCR product from the control cells could be detected (Figure 4). In contrast, a strong expression of TF mRNA could be observed in cells exposed to endotoxin. Captopril largely prevented the increase in TF mRNA. Southern blot analysis of GAPDH mRNA showed similar mRNA levels in control and endotoxin and captopril-treated cells, indicating that the efficiency of reverse transcription was comparable among the experimental groups. Amplification reactions performed without including reverse transcriptase gave no amplification products, thus ruling out PCR carryover.

**Effect of Captopril on Endotoxin Activation of c-Rel/p65 Heterodimers in Mononuclear Cells**

To determine whether captopril affected TF activity by preventing activation of c-Rel/p65 heterodimers, nuclear extracts of mononuclear cells exposed to endotoxin in the presence and in the absence of captopril were prepared and analyzed by EMSA. Nuclear localization of c-Rel/p65 heterodimers was induced within 1 hour after endotoxin stimulation (Figure 5). Captopril, at 20 μg/mL, almost completely abolished the translocation of c-Rel/p65 heterodimers induced by endotoxin.

To assess whether lymphocytes present in the mononuclear preparation could influence the effect of ACE inhibitors on TF, experiments were performed using preparations of Percoll-purified monocytes. Captopril consistently inhibited TF expression and mRNA levels and prevented c-Rel/p65 translocation in Percoll-purified monocytes, with an effect similar to that exerted in mononuclear cells (not shown).
Effect of captopril on nuclear translocation of c-Rel/p65 in endotoxin-stimulated mononuclear cells. Nuclear extracts were prepared from mononuclear cells untreated (lane 1) or treated with captopril (20 μg/mL) (lane 2), endotoxin (0.1 μg/mL) (lane 3), or both (lane 4) for 30 minutes at 37°C. The presence of c-Rel/p65 heterodimers was determined by EMSA.

Discussion

We provide here the first direct evidence that captopril reduces TF expression in endotoxin-stimulated human monocytes. Such an effect is attributable to ACE inhibition, given that molecules of different chemical structure, but with similar ACE inhibiting potential, exert a comparable effect. Inhibition of TF was observed at concentrations of captopril close to those reached in humans after its administration. The inhibitory action is exerted at the level of the biosynthesis of the TF protein, because captopril almost abolished the increase in mRNA levels that is observed when monocytes are exposed to endotoxin.

ACE converts angiotensin I into angiotensin II, which binds specific receptors, namely AT\textsubscript{1} and AT\textsubscript{2}, on cell membranes. Because activated monocytes have been shown to express angiotensin I and II, as well as AT\textsubscript{1} receptors, it is conceivable that, under the appropriate conditions, monocytes generate ACE, angiotensin II is formed, and occupancy of AT\textsubscript{1} receptor occurs. We found that endotoxin-stimulated monocytes express ACE activity in a dose-dependent fashion (data not shown), and this observation is in accordance with previous reports. Moreover, losartan, a specific antagonist of the AT\textsubscript{1} receptor family, inhibited TF activity to an extent similar to that observed with ACE inhibitors. This result is consistent with the hypothesis that TF expression in endotoxin-activated monocytes is regulated by endogenous angiotensin II.

Induction of the TF gene in monocytes by endotoxin is regulated by transcriptional factors. Stimulation of monocytes by endotoxin induces translocation of c-Rel/p65 heterodimers from the cytoplasm into the nucleus. Binding of the heterodimers to a regulatory κB element within the TF promoter induces its transcriptional activation. It has been shown that inhibition of the nuclear translocation of c-Rel/p65 abolishes TF gene induction in human monocytes.

A role for NF-κB activity in mediating functions pertinent to atherosclerosis has recently been supported by several studies. Inflammatory or proliferative stimuli that have been established to play a role in atherogenesis activate NF-κB in several cells. Nuclear localization of the NF-κB subunit p65 can be observed in situ in smooth muscle cells, endothelial cells, and macrophages within the fibrotic intima/media and atheromatous areas of the atherosclerotic lesion. In addition, it has recently been reported that transfecting rat hearts with a cis element decoy against NF-κB binding site attenuates ischemia reperfusion injury in the myocardium. Recently, an increase in NF-κB–like activity, monocyte chemoattractant protein-1 accumulation, and neointimal macrophage infiltration has been shown in atherosclerotic vessels during accelerated atherosclerosis in rabbits. Administration of the ACE inhibitor quinapril reduced these 3 parameters, suggesting that ACE inhibitors may have a beneficial effect in early atherosclerosis. Activation of NF-κB in humans with unstable angina has been reported. Our finding that captopril largely prevents endotoxin-induced c-Rel/p65 translocation to the promoter region of the gene encoding for TF in monocytes and lymphocyte-monocyte mixed preparations provides an additional link between ACE inhibitors and the pathogenesis of atherosclerosis.

The clinical use of ACE inhibitors has been proven to decrease the incidence of recurrent myocardial infarction, suggesting for these drugs a potential antithrombotic effect. The effect of these drugs appears to be related, at least in part, to mechanisms other than their antihypertensive action. In particular, the inhibition exerted either in vitro or in vivo on the synthesis of the proinflammatory cytokines interleukin-1 and tumor necrosis factor, which are involved in the recruitment of monocytes to atherosclerotic plaques, may play a major role. Our finding that ACE inhibitors and/or angiotensin II receptor antagonists downregulate TF expression by monocytes, together with the recent observation that enalapril decreased the amount of TF antigen in patients with uncomplicated acute myocardial infarction, suggests that the antithrombotic mechanism of these drugs could be, at least in part, related to their ability in reducing TF expression in monocytes. Because monocytes/macrophages are an integral part of atherosclerotic plaques, we speculate that, in conditions in which angiotensin II biosynthesis and/or activity is suppressed, the monocyte-associated TF present in atherosclerotic plaques might also be reduced. This is of particular relevance in light of the observation that platelet deposition and thrombus formation on atherosclerotic plaques is directly related to their TF content. Thus, the described capacity of angiotensin II synthesis inhibitors and/or receptor antagonists to modulate monocyte TF expression might have important therapeutic implications in patients with cardiovascular disease.
References


Angiotensin-Converting Enzyme Inhibitors Downregulate Tissue Factor Synthesis in Monocytes
Emanuela Napoleone, Angelomaria Di Santo, Marina Camera, Elena Tremoli and Roberto Lorenzet

Circ Res. 2000;86:139-143
doi: 10.1161/01.RES.86.2.139

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/86/2/139

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/